Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Retained Earnings: 2019-2025

Historic Retained Earnings for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$3.6 billion.

  • BridgeBio Pharma's Retained Earnings fell 28.15% to -$3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 billion, marking a year-over-year decrease of 28.15%. This contributed to the annual value of -$3.1 billion for FY2024, which is 20.92% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Retained Earnings stood at -$3.6 billion, which was down 5.30% from -$3.4 billion recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Retained Earnings peaked at -$1.0 billion during Q1 2021, and registered a low of -$3.6 billion during Q3 2025.
  • For the 3-year period, BridgeBio Pharma's Retained Earnings averaged around -$2.8 billion, with its median value being -$2.7 billion (2024).
  • Data for BridgeBio Pharma's Retained Earnings shows a maximum YoY crashed of 95.06% (in 2021) over the last 5 years.
  • Over the past 5 years, BridgeBio Pharma's Retained Earnings (Quarterly) stood at -$1.4 billion in 2021, then crashed by 33.49% to -$1.9 billion in 2022, then tumbled by 33.49% to -$2.6 billion in 2023, then declined by 20.92% to -$3.1 billion in 2024, then fell by 28.15% to -$3.6 billion in 2025.
  • Its Retained Earnings was -$3.6 billion in Q3 2025, compared to -$3.4 billion in Q2 2025 and -$3.3 billion in Q1 2025.